Thymosin β4 administration enhances fracture healing in mice.

Study summary

Main finding

Treated calluses had improved mechanical properties and more newly mineralized tissue at measured time points.

What was studied: Fibular osteotomy in mice treated with thymosin beta4
How the study was set up: Mice underwent bilateral fibular osteotomy and received full-length thymosin beta4 or saline.
What the researchers measured: Healing callus strength and stiffness, micro-CT mineralization, and microscopic bone composition were assessed.
How to read this evidence: Researchers studied cells, isolated tissue, or animals. These experiments can help explain a mechanism, but do not establish benefits or safety in people. Human cells grown in a laboratory also belong in this category.

Results in context

Stronger healing bone was reported in this experimental setting. Mechanical and imaging outcomes in mice do not determine human fracture-healing time.

What this does not establish

Mouse fracture measurements do not establish clinical bone healing or equivalence between thymosin beta4 and TB-500.

This collection includes related thymosin beta4 research. Parent or engineered peptide findings do not establish that a TB-500 fragment or a product sold under that name has the same effects.

Publication & source

Why this paper is included: The title focuses on thymosin beta4 or TB-500; parent-peptide findings do not establish TB-500 fragment effects.
Publication indexing: Journal Article · Research Support, Non-U.S. Gov't
Indexed subjects: Animals · Fibula · Fracture Healing · Fractures, Bone · Injections, Intraperitoneal · Male · Mechanical Phenomena · Mice · Mice, Inbred C57BL · Random Allocation · Thymosin · Thymosin beta(4)
Source checked: October 4, 2026. Years follow journal issues; online-first dates may differ.

Open PubMed record PMID 25042765 · Journal and full-text links

Educational research information. A publication does not verify the identity, quality, or safety of products sold here.

Back to TB-500 studies